PCN70 Cost Effectiveness Analysis Based on Progression Free Survival (PFS) of Pazopanib Versus Sunitinib for the Treatment of Advanced Renal Cell Carcinoma (ARCC) in the Mexican Context
Abstract
Authors
P. Anaya T.E. Delea P. Pichardo J.R. Diaz